<DOC>
	<DOCNO>NCT02006264</DOCNO>
	<brief_summary>This prospective , randomize , single-blinded , placebo control trial examine safety pharmacokinetics ( PK ) polyurethane tenofovir disoproxil fumarate ( TDF ) vaginal ring use continuously 14 consecutive day . The primary objective ass safety TDF vaginal ring use continuously 14 day healthy , HIV-uninfected , sexually abstinent woman , compare placebo vaginal ring .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Polyurethane Tenofovir Disoproxil Fumarate ( TDF ) Vaginal Ring</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<criteria>General good health ( volunteer history per investigator discretion ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) Willing give voluntary consent , sign inform consent form comply study procedure require protocol HIVuninfected base test perform study staff screening procedure Using low dose combine ( estrogen progesteronecontaining ) oral contraceptive pill ( include extendedcycle , 24 28day active pill regimens ) . Per participant report must use contraceptive method change prior 3 month intend use method duration study participation . Currently regular 28day menstrual cycle combine oral contraceptive pill . Normal Pap test screen appropriately document history Pap test complete followup abnormal pap test consistent American Congress Obstetricians Gynecologists ( ACOG ) practice guideline # 99 # 109 . Agrees participate research study involve drug , medical device , vaginal product duration study participation . Able willing refrain insert nonstudy vaginal product object vagina 48 hour prior Visit 2 throughout duration study . Able willing abstain oral , vaginal anal sex 48 hour prior Visit 2 throughout duration study . Women must meet none follow criterion prior genital sample Visit 2 : Known adverse reaction polyurethane component study product allergy silver nitrate Monsel 's solution . Hepatitis B infection ( define positive hepatitis B surface antigen ) . Chronic , recurrent , and/or acute vulvar vaginal symptom ( pain , irritation , spot , etc. ) . Known bleed disorder could lead prolonged continuous bleed biopsy . Pregnant intend become pregnant period study participation . Currently breastfeed breastfed infant last two month , plan breastfeed course study . Menopause . History unexplained unresolved intermenstrual bleed 3 month prior screen . History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix last 14 day . Hysterectomy . Use and/or anticipate use study period intravaginal intrauterine device . Systemic use last 2 week anticipate use study period follow : corticosteroid , antibiotic , antifungal , antiviral , anticoagulant antiretrovirals . Grade 1 high laboratory abnormality , per August 2009 update Division AIDS , National Institute Allergy Infectious Disease ( DAIDS ) Table Grading Severity Adverse Events ( AEs ) . In last six month , diagnose treat sexually transmit infection ( STI ) . Reproductive tract infection ( RTI ) pelvic inflammatory disease ( PID ) require treatment per current CDC guideline Screening Enrollment . Positive test Trichomonas vaginalis , Neisseria gonorrhea Chlamydia trachomatis screening . Reactive test syphilis screening . At Screening Enrollment , clinically apparent Grade 1 high pelvic exam finding ( observe study clinician designee ) per Division AIDS Table Grading Severity Adult Pediatric Adverse Events , Addendum 1 , Female Genital Grading Table Use Microbicide Studies .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>